Seven Fleet Capital Management LP Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 14,651 shares of the company’s stock, valued at approximately $604,000.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the period. Patient Square Capital LP acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth about $4,919,000. UBS Group AG raised its stake in shares of Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after buying an additional 469,547 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics during the 4th quarter valued at about $765,000. Finally, Fairmount Funds Management LLC lifted its holdings in shares of Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after buying an additional 600,000 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Up 0.7%

NASDAQ:DNTH opened at $82.49 on Friday. Dianthus Therapeutics, Inc. has a 52 week low of $16.64 and a 52 week high of $96.50. The stock has a market capitalization of $4.51 billion, a PE ratio of -19.97 and a beta of 1.18. The stock’s 50-day moving average price is $86.74 and its 200-day moving average price is $66.27.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DNTH. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday, March 9th. Oppenheimer boosted their price target on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 9th. Finally, Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $117.82.

Insider Buying and Selling at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the transaction, the senior vice president owned 30,000 shares in the company, valued at $2,424,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 179,121 shares of company stock valued at $15,059,454. Company insiders own 3.02% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.